ATE475706T1 - Abgeschwächter dengue-serotyp-2-stamm - Google Patents

Abgeschwächter dengue-serotyp-2-stamm

Info

Publication number
ATE475706T1
ATE475706T1 AT06755943T AT06755943T ATE475706T1 AT E475706 T1 ATE475706 T1 AT E475706T1 AT 06755943 T AT06755943 T AT 06755943T AT 06755943 T AT06755943 T AT 06755943T AT E475706 T1 ATE475706 T1 AT E475706T1
Authority
AT
Austria
Prior art keywords
strain
dengue serotype
attenuated dengue
attenuated
serotype
Prior art date
Application number
AT06755943T
Other languages
English (en)
Inventor
Richard Kinney
Claire Huang
Veronique Barban
Jean Lang
Bruno Guy
Original Assignee
Sanofi Pasteur
Ct S For Disease Control And P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur, Ct S For Disease Control And P filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE475706T1 publication Critical patent/ATE475706T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/08—Inactivation or attenuation by serial passage of virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT06755943T 2005-06-17 2006-06-07 Abgeschwächter dengue-serotyp-2-stamm ATE475706T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69127405P 2005-06-17 2005-06-17
PCT/IB2006/001513 WO2006134443A1 (en) 2005-06-17 2006-06-07 Dengue serotype 2 attenuated strain

Publications (1)

Publication Number Publication Date
ATE475706T1 true ATE475706T1 (de) 2010-08-15

Family

ID=37103341

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06755943T ATE475706T1 (de) 2005-06-17 2006-06-07 Abgeschwächter dengue-serotyp-2-stamm

Country Status (18)

Country Link
US (4) US7641908B2 (de)
EP (1) EP1891210B1 (de)
JP (1) JP5075120B2 (de)
KR (2) KR20080018271A (de)
CN (1) CN101238209B (de)
AR (1) AR053914A1 (de)
AT (1) ATE475706T1 (de)
AU (1) AU2006257621B2 (de)
BR (1) BRPI0613287A2 (de)
CA (1) CA2611954C (de)
DE (1) DE602006015807D1 (de)
IL (1) IL188068A0 (de)
MX (1) MX2007015872A (de)
MY (2) MY144542A (de)
NO (1) NO20076360L (de)
TW (1) TWI375722B (de)
WO (1) WO2006134443A1 (de)
ZA (1) ZA200710752B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006015807D1 (de) * 2005-06-17 2010-09-09 Ct S For Disease Control & Pre Abgeschwächter dengue-serotyp-2-stamm
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CN101139638B (zh) * 2007-05-08 2010-05-26 深圳太太基因工程有限公司 一种用于检测登革病毒ⅲ型核苷酸片段的引物和探针序列
CN105944095B (zh) 2008-03-05 2021-04-02 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
EP2143440A1 (de) 2008-07-09 2010-01-13 Sanofi Pasteur Stabilisierungssubstanz und Impfzusammensetzung, die ein oder mehrere abgeschwächte lebende Flaviviridae enthält
CN102449172A (zh) * 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
AU2010286368B2 (en) 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
CN102755642B (zh) * 2012-07-13 2014-01-08 中国食品药品检定研究院 一种炭疽疫苗的制备方法
KR20150036592A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 백신 조성물
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
EP2931310A4 (de) 2012-12-14 2016-05-25 Takeda Vaccines Inc Zusammensetzungen, verfahren zur verabreichung und verwendungen für dreiwertige dengue-virus-formulierungen
CA3177574C (en) * 2013-03-15 2026-03-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for dengue virus chimeric constructs in vaccines
EP3010536A4 (de) 2013-06-21 2016-11-30 Merck Sharp & Dohme Dengue-virus-impfstoffzusammensetzungen und verfahren zur verwendung davon
CN103382509A (zh) * 2013-07-17 2013-11-06 浙江国际旅行卫生保健中心 逆转录-环介导等温扩增检测登革2型病毒的试剂及检测方法
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
AU2015369875A1 (en) 2014-12-22 2017-06-15 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
EP3316905A1 (de) 2015-07-03 2018-05-09 Sanofi Pasteur Gleichzeitige impfung gegen dengue und gelbfieber
US10655110B2 (en) 2015-11-27 2020-05-19 Km Biologics Co., Ltd. Multivalent dengue vaccine composition comprising a mixture of attenuated dengue viruses from different serotypes
CN105999260B (zh) * 2016-05-13 2019-12-10 四川大学 氢氧化铝凝胶-氯化钠复合免疫佐剂及其制备方法和用途
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11590221B2 (en) 2018-09-05 2023-02-28 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
AU779280B2 (en) * 1999-03-26 2005-01-13 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
DE60040652D1 (de) * 2000-05-30 2008-12-11 Univ Mahidol Attenuierte Stammen von Denguevirus und ihre Verwendungen in Impfstoffzusammensetzungen
ATE434035T1 (de) 2000-09-25 2009-07-15 Polymun Scient Immunbio Forsch Lebender influenza impfstoff und verfahren zu seiner herstellung
CA2755964C (en) * 2001-05-22 2017-06-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
ES2355719T3 (es) * 2002-05-03 2011-03-30 The United States Government As Represented By The Department Of Health And Human Services Vacuna contra el dengue que contiene una deleción común de 30 nucleótidos en la utr en 3' del dengue tipos 1 y 2.
DE602006015807D1 (de) * 2005-06-17 2010-09-09 Ct S For Disease Control & Pre Abgeschwächter dengue-serotyp-2-stamm

Also Published As

Publication number Publication date
ZA200710752B (en) 2008-12-31
TWI375722B (en) 2012-11-01
DE602006015807D1 (de) 2010-09-09
WO2006134443A1 (en) 2006-12-21
US20100174057A1 (en) 2010-07-08
US7641908B2 (en) 2010-01-05
TW200738881A (en) 2007-10-16
EP1891210B1 (de) 2010-07-28
US8067566B2 (en) 2011-11-29
BRPI0613287A2 (pt) 2010-12-28
CN101238209B (zh) 2013-02-13
US20120083585A1 (en) 2012-04-05
CN101238209A (zh) 2008-08-06
KR101582163B1 (ko) 2016-01-05
JP2008546383A (ja) 2008-12-25
MX2007015872A (es) 2008-04-21
KR20140019034A (ko) 2014-02-13
AU2006257621B2 (en) 2011-08-11
AR053914A1 (es) 2007-05-23
AU2006257621A1 (en) 2006-12-21
US20150031857A1 (en) 2015-01-29
MY161457A (en) 2017-04-14
US20070026016A1 (en) 2007-02-01
JP5075120B2 (ja) 2012-11-14
US8795688B2 (en) 2014-08-05
NO20076360L (no) 2008-03-11
MY144542A (en) 2011-09-30
CA2611954C (en) 2014-01-28
EP1891210A1 (de) 2008-02-27
CA2611954A1 (en) 2006-12-21
KR20080018271A (ko) 2008-02-27
IL188068A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
ZA200710752B (en) Dengue serotype 2 attenuated strain
IL188041A0 (en) Dengue serotype 1 attenuated strain
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
DE602007009284D1 (de) 3-aza-bicycloä3.1.0ühexanderivate
DK2205562T3 (da) 1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
ATE535505T1 (de) Landwirtschaftliche zusammensetzung
DE502006000770D1 (de) Konservierungsmittel
ATE537171T1 (de) Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
DK1741339T3 (da) Pesticid sammensætning
EP1976974A4 (de) Pneumococcus-serotypen
DK1865813T3 (da) Fastgørelsesbøjle
FI20055434L (fi) Refraktometri
FI20055407L (fi) Kalanteri
DE502006003938D1 (de) Roststab
ATE538121T1 (de) 1,5,6-substituierte-2-oxo-3-cyano-1,6a- diazatetrahydrofluoranthene als antiinfektionsmittel
ATE412728T1 (de) Bleichmittel
EP1940415A4 (de) 19,23,24,25,26,27-hexanor-1alpha-hydroxyvitamin d3
DE502005007729D1 (de) Kalander
UA13036S (uk) Барна стійка
ITMI20050295U1 (it) Tovagliette sottopiatto migliorate
DE502006001048D1 (de) Kombileiste
ITFR20050004U1 (it) Traliccio "conte" muniti di due piattinecon tondino distanziatore
ITDP20060016A1 (it) Multisnodo 2
ITDP20060026A1 (it) Multisnodo 1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties